Liu Tao, Qian Wei-Jun, Gritsenko Marina A, Xiao Wenzhong, Moldawer Lyle L, Kaushal Amit, Monroe Matthew E, Varnum Susan M, Moore Ronald J, Purvine Samuel O, Maier Ronald V, Davis Ronald W, Tompkins Ronald G, Camp David G, Smith Richard D
Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington 99354, USA.
Mol Cell Proteomics. 2006 Oct;5(10):1899-913. doi: 10.1074/mcp.M600068-MCP200. Epub 2006 May 9.
Although human plasma represents an attractive sample for disease biomarker discovery, the extreme complexity and large dynamic range in protein concentrations present significant challenges for characterization, candidate biomarker discovery, and validation. Herein we describe a strategy that combines immunoaffinity subtraction and subsequent chemical fractionation based on cysteinyl peptide and N-glycopeptide captures with two-dimensional LC-MS/MS to increase the dynamic range of analysis for plasma. Application of this "divide-and-conquer" strategy to trauma patient plasma significantly improved the overall dynamic range of detection and resulted in confident identification of 22,267 unique peptides from four different peptide populations (cysteinyl peptides, non-cysteinyl peptides, N-glycopeptides, and non-glycopeptides) that covered 3,654 different proteins with 1,494 proteins identified by multiple peptides. Numerous low abundance proteins were identified, exemplified by 78 "classic" cytokines and cytokine receptors and by 136 human cell differentiation molecules. Additionally a total of 2,910 different N-glycopeptides that correspond to 662 N-glycoproteins and 1,553 N-glycosylation sites were identified. A panel of the proteins identified in this study is known to be involved in inflammation and immune responses. This study established an extensive reference protein database for trauma patients that provides a foundation for future high throughput quantitative plasma proteomic studies designed to elucidate the mechanisms that underlie systemic inflammatory responses.
尽管人血浆是发现疾病生物标志物的理想样本,但蛋白质浓度的极端复杂性和较大动态范围给表征、候选生物标志物的发现及验证带来了重大挑战。在此,我们描述了一种策略,该策略结合免疫亲和减除以及随后基于半胱氨酰肽和N - 糖肽捕获的化学分级分离与二维液相色谱 - 串联质谱,以扩大血浆分析的动态范围。将这种“分而治之”的策略应用于创伤患者血浆,显著提高了整体检测动态范围,并从四个不同肽群体(半胱氨酰肽、非半胱氨酰肽、N - 糖肽和非糖肽)中可靠鉴定出22,267种独特肽段,这些肽段覆盖了3,654种不同蛋白质,其中1,494种蛋白质由多个肽段鉴定。鉴定出了许多低丰度蛋白质,例如78种“经典”细胞因子和细胞因子受体以及136种人类细胞分化分子。此外,还鉴定出总共2,910种不同的N - 糖肽,它们对应于662种N - 糖蛋白和1,553个N - 糖基化位点。本研究中鉴定出的一组蛋白质已知参与炎症和免疫反应。这项研究为创伤患者建立了一个广泛的参考蛋白质数据库,为未来旨在阐明全身炎症反应潜在机制而设计的高通量定量血浆蛋白质组学研究奠定了基础。